Humedix휴메딕스
200670 · KOSDAQ · ₩200670 · 휴메딕스
₩23,000▼ ₩700 (2.95%)End-of-day · Oct 29, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩170B | ₩162B | ₩152B | ₩123B | ₩94B |
| Cost of sales | ₩91B | ₩87B | ₩82B | ₩69B | ₩59B |
| Gross profit | ₩80B | ₩75B | ₩70B | ₩55B | ₩35B |
| Operating income | ₩42B | ₩43B | ₩37B | ₩26B | ₩12B |
| Net income | ₩52B | ₩39B | ₩25B | ₩21B | ₩9B |
| Net income to shareholders | ₩52B | ₩39B | ₩25B | ₩21B | ₩9B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩324B | ₩250B | ₩220B | ₩227B | ₩196B |
| Current assets | ₩179B | ₩160B | ₩130B | ₩141B | ₩100B |
| Cash and equivalents | ₩40B | ₩110B | ₩80B | ₩91B | ₩9.4B |
| Total liabilities | ₩24B | ₩21B | ₩22B | ₩88B | ₩72B |
| Current liabilities | ₩21B | ₩19B | ₩20B | ₩85B | ₩38B |
| Borrowings | — | ₩0 | ₩0 | ₩32B | ₩30B |
| Total equity | ₩300B | ₩229B | ₩198B | ₩139B | ₩124B |
| Shareholders' equity | ₩300B | ₩229B | ₩198B | ₩139B | ₩124B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩45B | ₩51B | ₩31B | ₩38B | ₩18B |
| Capital spending | ₩7.9B | ₩8.6B | ₩9B | ₩7.2B | ₩13B |
| Free cash flow | ₩37B | ₩42B | ₩22B | ₩31B | ₩5.1B |
| Dividends paid | ₩11B | ₩6B | ₩7.1B | ₩3.8B | ₩3.8B |
Consolidated where available. Amounts in won.
Also known as: Humedix / 휴메딕스 / 200670 / KRX:200670
Source: KRX statistical information